Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 16612410.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
One reason for the inadequacy of current renoprotective therapy and the persistent poor renal prognosis in diabetic nephropathy is the large interindividual variation in response to treatment. Genetic as well as non-genetic factors are known to influence treatment efficacy. This Commentary summarizes the impact of the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism in the ACE gene on initiation and progression of diabetic nephropathy.
Medical subject headings
- Angiotensin-Converting Enzyme Inhibitors
- Diabetic Nephropathies
- Gene Deletion
- Genotype
- Mutagenesis, Insertional
- Peptidyl-Dipeptidase A